Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria - Concepedia

Concepedia

Publication | Closed Access

Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria

35

Citations

14

References

2004

Year

M. Hemels, Siegfried Kasper, E. Walter, Thomas R. Einarson

Current Medical Research and Opinion

Abstract

Escitalopram is a cost-effective alternative compared to (generic) citalopram in the first-line treatment of MDD in Austria.

References

	Year	Citations

Page 1